{"id":26333,"date":"2014-06-19T04:55:31","date_gmt":"2014-06-19T08:55:31","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=26333"},"modified":"2014-06-19T04:56:38","modified_gmt":"2014-06-19T08:56:38","slug":"endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333","title":{"rendered":"Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/19\/2014 (wallstreetpr) \u2013<b>\u00a0<\/b><b>Endocyte, Inc. (NASDAQ:ECYT)<\/b> and <b>Merck &amp; Co., Inc. (NYSE:MRK)<\/b> the two global health companies were working together on cancer therapy vintafolide. But now Merck will no longer be the part of the investigation. It has returned all the rights to cancer drug to Endocyte. European Regulators have given its conditional approval for the drug in March. Endocyte is not having a good time on the street right from the start of the year. The news of Merck leaving the project affected the stock price, leading to a fall of more than 13%.<\/p>\n<p style=\"text-align: justify;\"><b>The reasons for breakup<\/b><\/p>\n<p style=\"text-align: justify;\">Endocyte, Inc. (NASDAQ:ECYT)\u00a0and Merck were conducting a clinical trial of the cancer drug in the patients of ovarian cancer. However, the study failed shows any positive results. The drug was not working on the patients. There was no respite seen in the patients from the combination of vintafolide and chemotherapy.\u00a0 Seeing the failure, Merck decided to leave the investigation. Now Endocyte will have all the right to the experimental drug.<\/p>\n<p style=\"text-align: justify;\">It is a great jolt for Endocyte to handle the investigation alone. As Merck will no longer be a part of the development, Endocyte can face the financial problems to conduct the additional trials. It will also not have the support of the experienced sales staff in the future sales process.\u00a0 Endocyte has to find the solutions of both the problems.<\/p>\n<p style=\"text-align: justify;\"><b>The future plans<\/b><\/p>\n<p style=\"text-align: justify;\">Now when the experimental drug has failed to show any positive results in the treatment of Ovarian Cancer, Endocyte will opt for the experimenting the drug for the treatment of lung cancer. Endocyte, Inc. (NASDAQ:ECYT)\u00a0has already conducted a mid-stage study in patients suffering from non-small cell lung cancer. The data of the trial will be presented in a scientific meeting later this year. It remains to be seen what the drug can do in the lung cancer treatment. If it succeeds then, it can cover up the huge investigation costs of the company in the future.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/19\/2014 (wallstreetpr) \u2013\u00a0Endocyte, Inc. (NASDAQ:ECYT) and Merck &amp; Co., Inc. (NYSE:MRK) the two global health companies were working together on cancer therapy vintafolide. [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":26334,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[5412,1683,5413,1123],"stock_ticker":[],"class_list":["post-26333","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-endocyte-inc-nasdaqecyt","tag-merck-co-inc-nysemrk","tag-nasdaqecyt","tag-nysemrk","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/19\/2014 (wallstreetpr) \u2013\u00a0Endocyte, Inc. (NASDAQ:ECYT) and Merck &amp; Co., Inc. (NYSE:MRK) the two global health companies were working together on cancer therapy vintafolide. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-19T08:55:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-06-19T08:56:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Endocyte-Inc..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"316\" \/>\n\t<meta property=\"og:image:height\" content=\"159\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug\",\"datePublished\":\"2014-06-19T08:55:31+00:00\",\"dateModified\":\"2014-06-19T08:56:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333\"},\"wordCount\":346,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Endocyte-Inc..jpg\",\"keywords\":[\"Endocyte Inc. (NASDAQ:ECYT)\",\"Merck &amp; Co Inc. (NYSE:MRK)\",\"NASDAQ:ECYT\",\"NYSE:MRK\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333\",\"name\":\"Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Endocyte-Inc..jpg\",\"datePublished\":\"2014-06-19T08:55:31+00:00\",\"dateModified\":\"2014-06-19T08:56:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Endocyte-Inc..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Endocyte-Inc..jpg\",\"width\":316,\"height\":159},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333","og_locale":"en_US","og_type":"article","og_title":"Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug - Wall Street PR","og_description":"Boston, MA 06\/19\/2014 (wallstreetpr) \u2013\u00a0Endocyte, Inc. (NASDAQ:ECYT) and Merck &amp; Co., Inc. (NYSE:MRK) the two global health companies were working together on cancer therapy vintafolide. [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-06-19T08:55:31+00:00","article_modified_time":"2014-06-19T08:56:38+00:00","og_image":[{"width":316,"height":159,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Endocyte-Inc..jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug","datePublished":"2014-06-19T08:55:31+00:00","dateModified":"2014-06-19T08:56:38+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333"},"wordCount":346,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Endocyte-Inc..jpg","keywords":["Endocyte Inc. (NASDAQ:ECYT)","Merck &amp; Co Inc. (NYSE:MRK)","NASDAQ:ECYT","NYSE:MRK"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333","url":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333","name":"Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Endocyte-Inc..jpg","datePublished":"2014-06-19T08:55:31+00:00","dateModified":"2014-06-19T08:56:38+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Endocyte-Inc..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Endocyte-Inc..jpg","width":316,"height":159},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-to-handle-alone-the-development-of-cancer-drug-26333#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Endocyte, Inc. (NASDAQ:ECYT): To Handle Alone The Development Of Cancer Drug"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/26333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=26333"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/26333\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/26334"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=26333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=26333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=26333"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=26333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}